These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 37834095)

  • 1. Bortezomib Is Effective in the Treatment of T Lymphoblastic Leukaemia by Inducing DNA Damage, WEE1 Downregulation, and Mitotic Catastrophe.
    Din RU; Jiao A; Qiu Y; Mohan AAM; Yuen KC; Wong HT; Wan TM; Wong PO; Sin CF
    Int J Mol Sci; 2023 Sep; 24(19):. PubMed ID: 37834095
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sequential combination of bortezomib and WEE1 inhibitor, MK-1775, induced apoptosis in multiple myeloma cell lines.
    Barbosa RSS; Dantonio PM; Guimarães T; de Oliveira MB; Fook Alves VL; Sandes AF; Fernando RC; Colleoni GWB
    Biochem Biophys Res Commun; 2019 Nov; 519(3):597-604. PubMed ID: 31540690
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting WEE1 to enhance conventional therapies for acute lymphoblastic leukemia.
    Ghelli Luserna Di Rorà A; Beeharry N; Imbrogno E; Ferrari A; Robustelli V; Righi S; Sabattini E; Verga Falzacappa MV; Ronchini C; Testoni N; Baldazzi C; Papayannidis C; Abbenante MC; Marconi G; Paolini S; Parisi S; Sartor C; Fontana MC; De Matteis S; Iacobucci I; Pelicci PG; Cavo M; Yen TJ; Martinelli G
    J Hematol Oncol; 2018 Aug; 11(1):99. PubMed ID: 30068368
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synergistic induction of mitotic pyroptosis and tumor remission by inhibiting proteasome and WEE family kinases.
    Chen ZL; Xie C; Zeng W; Huang RQ; Yang JE; Liu JY; Chen YJ; Zhuang SM
    Signal Transduct Target Ther; 2024 Jul; 9(1):181. PubMed ID: 38992067
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The combination of bortezomib with chemotherapy to treat relapsed/refractory acute lymphoblastic leukaemia of childhood.
    Bertaina A; Vinti L; Strocchio L; Gaspari S; Caruso R; Algeri M; Coletti V; Gurnari C; Romano M; Cefalo MG; Girardi K; Trevisan V; Bertaina V; Merli P; Locatelli F
    Br J Haematol; 2017 Feb; 176(4):629-636. PubMed ID: 28116786
    [TBL] [Abstract][Full Text] [Related]  

  • 6. WEE1 inhibition induces glutamine addiction in T-cell acute lymphoblastic leukemia.
    Hu J; Wang T; Xu J; Wu S; Wang L; Su H; Jiang J; Yue M; Wang J; Wang D; Li P; Zhou F; Liu Y; Qing G; Liu H
    Haematologica; 2021 Jul; 106(7):1816-1827. PubMed ID: 31919076
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Role of Proteasome Inhibitors in Treating Acute Lymphoblastic Leukaemia.
    Sin CF; Man PM
    Front Oncol; 2021; 11():802832. PubMed ID: 35004327
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacological inactivation of CHK1 and WEE1 induces mitotic catastrophe in nasopharyngeal carcinoma cells.
    Mak JP; Man WY; Chow JP; Ma HT; Poon RY
    Oncotarget; 2015 Aug; 6(25):21074-84. PubMed ID: 26025928
    [TBL] [Abstract][Full Text] [Related]  

  • 9. WEE1 kinase targeting combined with DNA-damaging cancer therapy catalyzes mitotic catastrophe.
    De Witt Hamer PC; Mir SE; Noske D; Van Noorden CJ; Würdinger T
    Clin Cancer Res; 2011 Jul; 17(13):4200-7. PubMed ID: 21562035
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined inhibition of BCR-ABL1 and the proteasome as a potential novel therapeutic approach in BCR-ABL positive acute lymphoblastic leukemia.
    Maletzke S; Salimi A; Vieri M; Schroeder KM; Schemionek M; Masouleh BK; Brümmendorf TH; Koschmieder S; Appelmann I
    PLoS One; 2022; 17(10):e0268352. PubMed ID: 36194587
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergistic cytotoxic effects of bortezomib and CK2 inhibitor CX-4945 in acute lymphoblastic leukemia: turning off the prosurvival ER chaperone BIP/Grp78 and turning on the pro-apoptotic NF-κB.
    Buontempo F; Orsini E; Lonetti A; Cappellini A; Chiarini F; Evangelisti C; Evangelisti C; Melchionda F; Pession A; Bertaina A; Locatelli F; Bertacchini J; Neri LM; McCubrey JA; Martelli AM
    Oncotarget; 2016 Jan; 7(2):1323-40. PubMed ID: 26593250
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sequential drug treatment targeting cell cycle and cell fate regulatory programs blocks non-genetic cancer evolution in acute lymphoblastic leukemia.
    Malyukova A; Lahnalampi M; Falqués-Costa T; Pölönen P; Sipola M; Mehtonen J; Teppo S; Akopyan K; Viiliainen J; Lohi O; Hagström-Andersson AK; Heinäniemi M; Sangfelt O
    Genome Biol; 2024 May; 25(1):143. PubMed ID: 38822412
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Wee1 Kinase: A Potential Target to Overcome Tumor Resistance to Therapy.
    Esposito F; Giuffrida R; Raciti G; Puglisi C; Forte S
    Int J Mol Sci; 2021 Oct; 22(19):. PubMed ID: 34639030
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased activity of both CDK1 and CDK2 is necessary for the combinatorial activity of WEE1 inhibition and cytarabine.
    Garcia TB; Fosmire SP; Porter CC
    Leuk Res; 2018 Jan; 64():30-33. PubMed ID: 29175378
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The proteasome inhibitor bortezomib acts independently of p53 and induces cell death via apoptosis and mitotic catastrophe in B-cell lymphoma cell lines.
    Strauss SJ; Higginbottom K; Jüliger S; Maharaj L; Allen P; Schenkein D; Lister TA; Joel SP
    Cancer Res; 2007 Mar; 67(6):2783-90. PubMed ID: 17363600
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proteasome subunit expression analysis and chemosensitivity in relapsed paediatric acute leukaemia patients receiving bortezomib-containing chemotherapy.
    Niewerth D; Kaspers GJ; Jansen G; van Meerloo J; Zweegman S; Jenkins G; Whitlock JA; Hunger SP; Lu X; Alonzo TA; van de Ven PM; Horton TM; Cloos J
    J Hematol Oncol; 2016 Sep; 9(1):82. PubMed ID: 27599459
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mitotic Checkpoints and the Role of WEE1 Inhibition in Head and Neck Squamous Cell Carcinoma.
    Khan SN; Swiecicki PL; Doroshow DB
    Cancer J; 2022 Sep-Oct 01; 28(5):381-386. PubMed ID: 36165727
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proteasome inhibition enhances the efficacy of volasertib-induced mitotic arrest in AML in vitro and prolongs survival in vivo.
    Schnerch D; Schüler J; Follo M; Felthaus J; Wider D; Klingner K; Greil C; Duyster J; Engelhardt M; Wäsch R
    Oncotarget; 2017 Mar; 8(13):21153-21166. PubMed ID: 28416751
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bortezomib interferes with adhesion of B cell precursor acute lymphoblastic leukemia cells through SPARC up-regulation in human bone marrow mesenchymal stromal/stem cells.
    Iwasa M; Miura Y; Fujishiro A; Fujii S; Sugino N; Yoshioka S; Yokota A; Hishita T; Hirai H; Andoh A; Ichinohe T; Maekawa T
    Int J Hematol; 2017 May; 105(5):587-597. PubMed ID: 28044259
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cell death by bortezomib-induced mitotic catastrophe in natural killer lymphoma cells.
    Shen L; Au WY; Wong KY; Shimizu N; Tsuchiyama J; Kwong YL; Liang RH; Srivastava G
    Mol Cancer Ther; 2008 Dec; 7(12):3807-15. PubMed ID: 19074855
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.